Home > Boards > US OTC > Biotechs >

Atheronova, Inc. (AHROQ)

Add AHROQ Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/14/2017 12:30:22 PM - Followers: 15 - Board type: Free - Posts Today: 0


AtheroNova is an early stage biotech company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. AtheroNova has developed intellectual property for a class of compounds that have the potential to significantly reduce the incidence and severity of atherosclerosis.

Existing classes of cholesterol reduction drugs, including statins, have demonstrated market success, rapidly achieving blockbuster status and billions of dollars in sales without demonstrating any efficacy at reducing atherosclerosis at commonly used dosage levels. Only one study demonstrated even minimal efficacy at reducing plaque, and then only on patients taking the maximum approved dosage for two years.

Although additional research and development is required, AtheroNova has the potential to produce atherosclerosis drugs that will regress or eliminate atherosclerotic fatty plaques. The Company is currently completing two additional studies to validate the efficacy findings of its initial study and prepare for upcoming human trials. The Company plans to develop multiple applications for its compounds.


AHRO Security Details
Share Structure
Market Value1 $30,529,182 a/o Nov 16, 2011
Shares Outstanding 27,753,802 a/o Oct 27, 2011
Float Not Available
Authorized Shares 100,000,000 a/o Jun 30, 2011
Par Value 0.001
Shareholders of Record 70 a/o Mar 31, 2011
Security Notes
  • Capital Change=shs decreased by 1 for 10 split Pay date=06/30/2006.
  • Capital Change=shs decreased by 1 for 200 split; + Shareholders of 1-99 shares pre-split will receive the same number of shares post-split. Shareholders of 100 - 19,999 pre-split shares will hold no fewer than 100 post-split shares. Share holders of 20,000 or more share. Pay date=06/28/2010.
Short Selling Data
Short Interest 0 (-100%)
Oct 31, 2011
Significant Failures to Deliver No
Transfer Agent(s)
Securities Transfer Corp.

Contact Info
  • 2301 Dupont Drive
  • Suite 525
  • Irvine, CA 92612

Index Membership: N/A
Sector: Financial
Industry: Real Estate Development
Full Time Employees: 2


Business Description

AtheroNova Inc. is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of cardiovascular disease and the leading killer in industrialized nations worldwide. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.

Key Investment Considerations

$41+ Billion market potential
Strong IP protection
Identifiable milestones 
Potentially lower risk of safety or efficacy problems than is typical in drug development
Strong management team with successful track record
Capital structure

Our Company
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company is currently conducting two additional animal studies to validate the findings of its initial study and prepare for human trials. AtheroNova plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products, for the treatment of atherosclerosis.
Our Technology
Our intellectual property for treating atherosclerosis began with the ideas of our two founding shareholders, Dr. Giorgio Zadini and Dr. Filiberto Zadini, co-inventors of our technology.  Their research, covered by our patent applications, uses certain pharmalogical compounds for the treatment of atherosclerosis.  Through a process called delipidization, such compounds dissolve plaques in artery walls so they are removed through normal body processes.  The compounds go through the atherosclerotic fibrous cap and, through delipidization, cause rapid reduction in the size of the deposits of soft vulnerable plaque in an artery's walls.  We also believe that the artery walls, once delipidized, will undergo a marked reduction in inflammation and ultimately undergo a significant restoration of their integrity.  The compounds can be used to reverse the effects of existing atherosclerosis by widening the area in an artery through which the blood flows and avoiding the rupturing and dislodging of chunks of the hardened plaque.  The compounds can also be used to prevent significant plaque buildups in arteries from occurring.
Besides applications in atherosclerosis, delipidization has significant applications in other medical fields.  The delipidization of subcutaneous fat has been scientifically demonstrated by researchers at a leading U.S. academic institution, and was achieved utilizing one of the compounds determined by us to be an effective delipidizing compound.  This has possibly significant implications for use in the field of clinical cosmesis, for which we have developed certain intellectual property for delipidization application to unwanted subcutaneous fat through transdermal delivery.
There are other promising potential areas of application for our intellectual property that merit further exploration and testing.  We believe that systemic application of our delipidizing pharmacological compounds may have beneficial effects in the treatment of obesity and some of the disorders associated with obesity such as hypertension, diabetes, etc.  We also believe that cleansing the lipid buildup from the small peripheral vessels in the body via delipidization will have beneficial effects on overall human physiology and well-being.
Atherosclerosis (from the Greek words "athero" (gruel or paste) and "sclerosis" (hardness)) is a common disease of the arteries.  It occurs when organic materials, primarily cholesterol (the waxy, fat-like material found in all parts of the body) or fats, are deposited and harden in the walls of arteries.  This may occur when such materials accumulate under a fibrotic cap or at a tear in the inner lining of an artery.
As the deposits harden, they can restrict and occlude the area through which the blood can flow through an artery, thereby reducing the amount of blood made available to organs and other parts of the body.  Restricted blood flow in the arteries, such as to the heart muscle, can lead to symptoms such as chest pain.  It also can cause tissues to receive inadequate oxygen, which is directly related to a number of circulatory disorders.  For example, arteriosclerosis of the extremities is a disease of the peripheral blood vessels that is characterized by narrowing and hardening of the arteries that supply the arms, legs and feet.  The narrowing of the arteries causes a decrease or cessation in blood flow.  Symptoms include pain, numbness, cold tissues and hypoxia resulting in cellular death.
Hardened plaques can also rupture and dislodge from an artery's walls, and then greatly restrict or block altogether blood flow through that or other arteries.  This can lead to heart attacks and other severe disorders.  For example, strokes can be caused when ruptured plaques in a neck artery impede the flow of blood to parts of the brain and decrease brain functions.
Cardiovascular disease is the leading cause of morbidity, disability and mortality in industrialized countries, and atherosclerosis is its main underlying pathology.
  We are currently conducting two progressive laboratory studies of the technology.  These studies are expected to cost approximately $400,000 and take 6-8 months to complete, and an additional 3-4 months to determine the final results.
The global medical industry presently, through many large and small health care providers and other vendors of goods and services, generates substantial cash flows directly related to the treatment of symptomatic atherosclerotic disease.  The clinical applications of our intellectual property are expected to be a novel class of pharmacological compounds for treating and preventing atherosclerosis, suitable for parenteral, oral, transdermal and in-loco methods of delivery.  The therapeutic applications of our intellectual property within such a variety of clinical modalities are likely to be both synergistic and disruptive to the types of clinical care presently applied within the atherosclerosis-related markets.   
Existing markets sectors, with their approximate annual cash flows, include Serum Screening ($3 Billion), Imaging ($12 Billion), Diagnostic Catheterizations ($12 Billion), Statin Drug Therapies ($10 Billion) and Drug Eluting Stents ($6 Billion).  In addition, incalculable investment dollars are applied to emerging therapeutic technologies for cardiovascular diseases.
            Safety and Regulatory Approvals
The compounds used in our technology have a history of approval for use in humans by regulatory government agencies in a large number of developed countries throughout the world, including Germany, England, France, and Italy, and have been used in humans throughout the world, including in the USA, for their medical indications.  The existing human safety record for this class of compounds, at higher concentrations than we required in our initial research, is well established for uses other than those which we have claimed in our intellectual property.  Use of the compounds in such other medical configurations, though approved, is limited to non-competing clinical applications that cannot be diverted or used off-label for the uses covered by our patent applications.

Barchart.com Technical Analysis
Medium Term Indicators Average: 25% Buy
50-Day Average Volume - 6,468
Long Term Indicators  
Get Chart Get Performance 60 Day Commodity Channel Index   Hold  
Get Chart Get Performance 100 Day Moving Average vs Price Buy    
Get Chart Get Performance 50 - 100 Day MACD Oscillator Buy    
Long Term Indicators Average: 67% Buy
100-Day Average Volume - 9,595
Overall Average: 8% Buy
Price Support Pivot Point Resistance
1.4500 0.6833 1.2833 1.8833
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#332   $AHROQ: Told you it was gonna continue to DROP makinezmoney 09/14/17 12:30:22 PM
#331   $AHROQ: Bidding $0.0045 on it......... makinezmoney 09/13/17 10:09:59 AM
#330   Today's pick is: AHROQ Let’s get right to it… My GhosTraderX 09/13/17 09:24:01 AM
#329   insane pump you guys had going here. CaptainCourageous 09/08/17 01:00:16 PM
#328   CDVIQ has almost no volume lol... retireat40 09/08/17 12:43:16 PM
#327   The easiest, pretty much a garbage site, but Full Contact Yoga 09/08/17 11:57:35 AM
#326   Can you send me the sites you used PennyLearning 09/08/17 11:47:25 AM
#325   That's hard to say, depends on your broker Full Contact Yoga 09/08/17 10:38:06 AM
#324   if i put in a purchase of 250,000 SuperAm 09/08/17 10:31:56 AM
#323   Awesome !!!! The Penny Reaper 09/08/17 10:14:49 AM
#322   I got lucky, filled most of my bid Full Contact Yoga 09/08/17 09:58:16 AM
#321   $AHROQ: Interesting Q play here... $CDVIQ is better makinezmoney 09/08/17 09:58:10 AM
#320   P & D: http://www.theotc.today/ davidsson10 09/08/17 09:57:21 AM
#319   I never jumped in... saw at .009 then The Penny Reaper 09/08/17 09:51:14 AM
#318   Absolutely, quick hit, then, run for the hills, Full Contact Yoga 09/08/17 09:50:21 AM
#317   Fantastic news! > Run away > huge upside! crudeoil24 09/08/17 09:49:52 AM
#316   Pump and dump today! Get in and out quick! The Penny Reaper 09/08/17 09:35:01 AM
#315   To expensive yet, wait for a forward spilt eddy2 07/20/17 01:13:47 PM
#314   NOT a good thing at all: retireat40 05/24/16 11:27:42 AM
#313   AHROQ .015 x .025 bankruptcy case dismissed: $treet Trader 05/24/16 11:24:29 AM
#311   AtheroNova has filed for Chapter 11, and while ather 03/19/15 04:24:17 PM
#310   I'm trying to figure out, if AHROQ was CerealManStocks 03/13/15 02:03:26 PM
#309   Been following. Don't own. smitter 03/11/15 12:38:51 PM
#308   Hey, smitty !!! Louis Rukeyser 03/11/15 12:38:11 PM
#307   Yeppers smitter 03/11/15 12:04:18 PM
#306   another nice *POP* 2day on very few shares [SMART MONEY] 03/10/15 11:55:53 PM
#305   AHRO changed to AHROQ: bankruptcy: Renee 03/03/15 05:23:04 PM
#304   Funny. A penny stock ($0.05) filed bankruptcy. So, gm99 03/03/15 02:03:11 PM
#303   Nice job. I tried to do the benchman 03/03/15 10:24:03 AM
#302   well at least sumbody bought 57k @ .0121 [SMART MONEY] 03/03/15 10:22:34 AM
#301   Chapter 11 bankrupcy is different than standard bankrupcy golfstar03 03/03/15 09:42:09 AM
#300   Yeah, nice job holding off. benchman 03/03/15 09:31:49 AM
#299   Thanks God I didn't buy I was very Eltp 03/03/15 09:28:29 AM
#298   Thank God I sold again yesterday. benchman 03/03/15 09:13:26 AM
#297   AtheroNova and its Subsidiary File for Chapter 11 [SMART MONEY] 03/03/15 09:07:31 AM
#296   try zero--just filed Bankruptcy power_forward 03/03/15 09:00:40 AM
#295   If the person who is trying to buy benchman 02/26/15 02:48:13 PM
#294   Bought another starter at .06 again. GLTA benchman 02/25/15 11:01:03 AM
#293   It was! Made a nice profit it benchman 02/23/15 08:24:23 AM
#292   nice starter! @ .056 [SMART MONEY] 02/22/15 11:37:34 PM
#291   They have $1 million cash to pay more FredVestor 02/20/15 10:07:54 AM
#290   I am in at .056. Think we benchman 02/17/15 02:38:14 PM
#288   I'm not saying this is a recent thing. FredVestor 02/17/15 09:30:18 AM
#287   This is no where near a pump and dump. golfstar03 02/17/15 09:19:42 AM
#286   You can forget about survival. This thing will FredVestor 02/17/15 09:14:49 AM
#285   I agree that the Top Line test results ather 02/16/15 10:30:27 PM
#284   We need positive trial results like yesterday for dubbya 02/16/15 01:40:08 PM
#283   besides it not being very good, defaulting on pitacorp 02/16/15 12:36:42 PM
#282   ARHO to da trips by next month . DeafTrader2 02/15/15 07:19:50 PM
Consent Preferences